Cybec Dosage/Direction for Use

Recommended Dose: Celecoxib capsule, at doses up to 200 mg twice per day can be taken with or without food.
As the cardiovascular (CV) risks of Celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
Osteoarthritis (OA): The recommended dose of Celecoxib is 200 mg as a single dose. In some patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after 2 weeks, other therapeutic options should be considered.
Rheumatoid arthritis (RA): The recommended dose of Celecoxib is 200 mg twice per day.
Acute pain and primary dysmenorrhea: The recommended dose of Celecoxib is 400 mg initially, followed by an additional 200 mg dose if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily or 400 mg once daily as needed.
Ankylosing Spondylitis (AS): The recommended dose of Celecoxib is 200 mg administered as a single dose. Some patients may benefit from a total daily dose of 400 mg.
Low back pain (LBP): The recommended dose of Celecoxib is 200 mg or 400 mg daily, administered as a 200 mg single dose, or as 200 mg twice per day. Some patients may benefit from a total daily dose of 400 mg.
Use in the elderly: No dosage adjustment is necessary. However, for elderly patients weighing lower than 50 kg, it is recommended to initiate therapy at the lowest recommended dose.
Hepatic impairment: No dosage adjustment is necessary in patients with mild hepatic impairment (Child-Pugh Class A). Introduce Celecoxib at half the recommended dose in arthritis patients with moderate hepatic impairment (Child-Pugh Class B).
The use of Celecoxib in patients with severe hepatic impairment (Child-Pugh Class C) is not recommended.
Renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Celecoxib has not been evaluated in patients with severe renal impairment. If Celecoxib therapy must be used in patients with severe renal impairment, close monitoring of renal function is recommended.
400 mg: CYP2C9 poor metabolizers: Patients who are known, or suspected to be CYP2C9 poor metabolizers based on previous history/experience with other CYP2C9 substrates should be administered Celecoxib with caution. Consider starting treatment at half the lowest recommended dose.
Co-administration with fluconazole: Celecoxib should be introduced at half the recommended dose in patients receiving fluconazole, a CYP2C9 inhibitor. Caution is advised when co-administering Celecoxib with other CYP2C9 inhibitors.
Pediatric patients: Celecoxib has not been studied in subjects under 18 years of age.